Palabras clave
Embarazo
COVID-19
Diagnóstico
Tratamiento
Cómo citar
Copyright © | Todos los derechos reservados.
La revista posee los derechos de autor exclusivos para la publicación de este artículo en los términos de la ley brasileña 9610/98.
Reproducción parcial
El uso de partes de los textos, figuras y cuestionario del artículo es libre, siendo obligatoria la citación de los autores y revista.
Reproducción total
Está expresamente prohibido y debe ser autorizado por la revista.
Resumen
Objetivo: Evaluar las principales actualizaciones sobre la influencia de la diabetes mellitus (DM1) en el embarazo, las enfermedades cardiovasculares y COVID-19, así como la genética y tratamiento de la enfermedad. Revisión bibliográfica: DM1 es una enfermedad autoinmune compleja, marcada por la pérdida de células β pancreáticas, lo que conduce a una producción insuficiente de insulina. Su incidencia ha crecido en todo el mundo desde la década de 1950, aumentando entre un 3% y un 4% en las últimas tres décadas. La DM1 tiene implicaciones importantes para afecciones como la hipertensión, la enfermedad arterial periférica y coronaria, y sus portadores pueden tener un mayor riesgo de sufrir complicaciones relacionadas con el COVID-19. Las mujeres embarazadas con DM1 presentan riesgos obstétricos y neonatales adversos. El tratamiento de la enfermedad implica la administración de insulina y los avances recientes se han centrado en promover un mejor control glucémico y reducir el riesgo de complicaciones. Consideraciones finales: El diagnóstico y tratamiento precoz de la DM1 repercute en la morbimortalidad de los pacientes, ya que evita complicaciones durante el desarrollo de otras enfermedades simultáneas y mejora la calidad de vida de las personas que la padecen. Es importancia que el equipo multidisciplinario se mantenga actualizado y busque innovaciones sobre la enfermedad.
Referencias
AKIL AA, et al. Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era. J Transl Med, 2021; 19(1): 137.
AMERICAN DIABETES ASSOCIATION. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care, 2020; 43(1): 14-31.
BARRETT CE, et al. Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years - United States, March 1, 2020-June 28, 2021. MMWR Morb Mortal Wkly Rep, 2022; 71(2): 59-65.
BECK RW, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. Jama, 2017; 317(4): 371-378.
BENHALIMA K, et al. Management of type 1 diabetes in pregnancy: update on lifestyle, pharmacological treatment, and novel technologies for achieving glycaemic targets. Lancet Diabetes Endocrinol, 2023; 11(7): 490-508.
Chen S, Du K, Zou C. Current progress in stem cell therapy for type 1 diabetes mellitus. Stem Cell Res Ther. 2020 Jul 8;11(1): 275.
CICHOCKA E, et al. Adjuvant therapy in type 1 diabetes mellitus. Endokrynol Pol, 2021; 72(1): 87-88.
COBAS R, et al. Diagnóstico do diabetes e rastreamento do diabetes tipo 2. Diretriz Oficial da Sociedade Brasileira de Diabetes. 2023. Disponível em: https ://diretriz.diabetes.org.br/diagnostico-e-rastreamento-do-diabetes-tipo-2/#citacao. Acessado em: 31 de março de 2024.
DIMEGLIO LA. COVID-19 and Type 1 Diabetes: Addressing Concerns and Maintaining Control. Diabetes Care, 2021; 44(9): 1924-1928.
DINNYES A, et al. Integration of nano- and biotechnology for beta-cell and islet transplantation in type-1 diabetes treatment. Cell Prolif, 2020; 53(5): 12785.
DOST A, et al. 2017 American Academy of Pediatrics Clinical Practice Guideline: Impact on Prevalence of Arterial Hypertension in Children and Adolescents With Type 1 Diabetes. Diabetes Care, 2020; 43(6): 1311-1318.
ELIASSON B, et al. The significance of chronic kidney disease, heart failure and cardiovascular disease for mortality in type 1 diabetes: nationwide observational study. Sci Rep, 2022; 12(1): 17950.
HAAK T, et al. Therapy of Type 1 Diabetes. Exp Clin Endocrinol Diabetes, 2019; 127(1): 27-38.
HELMAN A e MELTON DA. A Stem Cell Approach to Cure Type 1 Diabetes. Cold Spring Harb Perspect Biol. 2021; 13(1): 35741.
HOGREBE NJ, et al. Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes. Cell Stem Cell, 2023; 30(5): 530-548.
IMAFUKU H, et al. Advantages of sensor-augmented insulin pump therapy for pregnant women with type 1 diabetes mellitus. J Diabetes Investig, 2023; 14(12): 1383-1390.
JAFFAR F, et al. Type 1 Diabetes in Pregnancy: A Review of Complications and Management. Curr Diabetes Ver, 2022; 18(7): 051121197761.
JULIÁN MT, et al. The double burden: type 1 diabetes and heart failure-a comprehensive review. Cardiovasc Diabetol, 2024; 23(1): 65.
LITHOVIUS R, et al. The many faces of hypertension in individuals with type 1 diabetes. Diabetes Res Clin Pract, 2023; 197: 110564.
LIU Z, et al. Causal associations between type 1 diabetes mellitus and cardiovascular diseases: a Mendelian randomization study. Cardiovasc Diabetol, 2023; 22(1): 236.
LORETELLI C, et al. Cell therapy for type 1 diabetes. Expert Opinion on Biological Therapy, 2020; 20(8): 887–897.
MCGLACKEN-BYRNE SM, et al. The SARS-CoV-2 pandemic is associated with increased severity of presentation of childhood onset type 1 diabetes mellitus: a multi-centre study of the first COVID-19 wave. Diabet. Med, 2021; 38(9): 14640.
NWOKOLO M e HOVORKA R. The Artificial Pancreas and Type 1 Diabetes. J Clin Endocrinol Metab. 2023; 108(7): 1614-1623.
PASTORE I, et al. The impact of diabetes mellitus on the onset of cardiovascular risk in children and teenagers. Int J Mol Sci, 2020; 21(14): 4928.
PENG X, et al. Preclinical models for Type 1 Diabetes Mellitus - A practical approach for research. Int J Med Sci, 2023; 20(12): 1644-1661.
PITOCCO D, et al. Lack of type 1 diabetes involvement in SARS-COV-2 population: Only a particular coincidence? Diabetes Res. Clin. Pract, 2020; 164: 108220.
PRATLEY RE, et al. Wireless Innovation for Seniors With Diabetes Mellitus (WISDM) Study Group. Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2020; 323(23): 2397-2406.
PRIMAVERA M, et al. Prediction and Prevention of Type 1 Diabetes. Front Endocrinol (Lausanne), 2020; 11: 248.
QU HQ, et al. Improved genetic risk scoring algorithm for type 1 diabetes prediction. Pediatr Diabetes, 2022; 23(3): 320-323.
RANKIN D, et al. Rollout of Closed-Loop Technology to Pregnant Women with Type 1 Diabetes: Healthcare Professionals' Views About Potential Challenges and Solutions. Diabetes Technol Ther, 2023; 25(4): 260-269.
REDONDO MJ, et al. Type 1 diabetes in diverse ancestries and the use of genetic risk scores. Lancet Diabetes Endocrinol, 2022; 10(8): 597-608.
RODACKI M, et al. Classificação do diabetes. Diretriz Oficial da Sociedade Brasileira de Diabetes. 2023. Disponível em: https ://diretriz.diabetes.org.br/classificacao-do-diabetes/#citacao. Acessado em: 25 de março de 2024.
RODRIGUES OLIVEIRA SM, et al. Type 1 Diabetes Mellitus: A Review on Advances and Challenges in Creating Insulin Producing Devices. Micromachines (Basel). 2023;14(1): 151.
RUBINO F, et al. New-onset diabetes in Covid-19. New England Journal of Medicine, 2020; 383(8): 789-790.
SANCHEZ M, et al. Leukocyte telomere length, allelic variations in related genes and risk of coronary heart disease in people with long-standing type 1 diabetes. Cardiovasc Diabetol, 2022; 21(1): 206.
TANG X, et al. Fulminant type 1 diabetes after COVID-19 vaccination. Diabetes Metab, 2022; 48(2): 101324.
TOMMERDAHL KL, et al. Early microvascular complications in type 1 and type 2 diabetes: recent developments and updates. Pediatr Nephrol, 2022; 37(1): 79-93.
UNSWORTH R, et al. New-onset type 1 diabetes in children during COVID-19: multicenter regional findings in the U.K. Diabetes Care, 2020; 43(11): 170-171.
WEISS A, et al. Type 1 Diabetes Incidence and Risk in Children With a Diagnosis of COVID-19. JAMA, 2023; 329(23): 2089-2091.
YAPANIS M, et al. Complications of Diabetes and Metrics of Glycemic Management Derived From Continuous Glucose Monitoring. J Clin Endocrinol Metab, 2022; 107(6): 2221-2236.